| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITLN1 |
| Uniprot No | Q8WWA0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-313aa |
| 氨基酸序列 | WSTD EANTYFKEWT CSSSPSLPRS CKEIKDECPS AFDGLYFLRT ENGVIYQTFC DMTSGGGGWT LVASVHENDM RGKCTVGDRW SSQQGSKAVY PEGDGNWANY NTFGSAEAAT SDDYKNPGYY DIQAKDLGIW HVPNKSPMQH WRNSSLLRYR TDTGFLQTLG HNLFGIYQKY PVKYGEGKCW TDNGPVIPVV YDFGDAQKTA SYYSPYGQRE FTAGFVQFRV FNNERAANAL CAGMRVTGCN TEHHCIGGGG YFPEASPQQC GDFSGFDWSG YGTHVGYSSS REITEAAVLL FYR |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ITLN1重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *"Recombinant human intelectin suppresses bacterial proinflammatory activity through pathogen recognition"*
**作者**: Lee SH, et al.
**摘要**: 该研究利用大肠杆菌表达系统成功制备了重组人ITLN1蛋白，证明其能通过识别病原体相关分子模式(如脂磷壁酸)抑制细菌诱导的炎症反应，揭示了ITLN1在先天免疫中的潜在作用。
2. **文献名称**: *"Expression and characterization of recombinant murine intelectin-1: a role in glucose metabolism"*
**作者**: Suzuki YA, et al.
**摘要**: 通过哺乳动物细胞表达系统获得重组小鼠ITLN1.发现其与脂肪细胞表面结合并调节葡萄糖摄取，提示ITLN1可能在胰岛素敏感性和代谢疾病中发挥作用。
3. **文献名称**: *"Structural insights into human intelectin-1: Cryo-EM analysis of the oligomeric state and carbohydrate interaction"*
**作者**: Vossenkämper A, et al.
**摘要**: 通过冷冻电镜解析重组人ITLN1的三维结构，发现其形成三聚体并通过特定结构域结合糖类分子，为理解其病原体识别和信号转导机制提供结构基础。
---
注：以上文献为模拟示例，实际文献需通过学术数据库(如PubMed)检索确认。建议结合关键词“ITLN1 recombinant”“Intelectin-1 expression”进一步查阅最新研究。
ITLN1 (Intelectin-1), also known as omentin, is a calcium-dependent lectin encoded by the ITLN1 gene. It is primarily secreted by visceral adipose tissue, intestinal goblet cells, and immune cells. Structurally, it belongs to the intelectin family, characterized by a fibrinogen-like domain and a unique carbohydrate recognition domain. ITLN1 binds specifically to galactofuranose residues in microbial glycans and endogenous glycoconjugates, implicating its role in innate immunity, pathogen recognition, and host-microbe interactions.
Recombinant ITLN1 protein is engineered using genetic cloning techniques, often expressed in mammalian cell systems (e.g., HEK293) or prokaryotic systems (e.g., E. coli) to ensure proper folding and post-translational modifications. Purification typically involves affinity chromatography, yielding high-purity protein for functional studies. Its production enables researchers to explore ITLN1's biological mechanisms, including its dual role in metabolic regulation and inflammation. Notably, ITLN1 exhibits adipokine-like properties, modulating insulin sensitivity and adipose tissue inflammation, while also acting as a pattern recognition receptor against pathogens like bacteria and fungi.
Clinically, ITLN1 is linked to metabolic disorders (e.g., obesity, diabetes), inflammatory bowel disease, and cancer. Reduced circulating ITLN1 levels correlate with insulin resistance and cardiovascular risk, whereas its anti-inflammatory effects are being investigated in autoimmune conditions. Recombinant ITLN1 serves as a critical tool for structural analysis, ligand-binding assays, and therapeutic development, including potential applications in microbiome modulation or metabolic syndrome treatment. Ongoing research aims to clarify its signaling pathways and therapeutic potential, balancing its metabolic and immunological functions.
×
